SCHEDULE 13G/A: Paradigm BioCapital Entities Report Passive Stake in Disc Medicine, Inc.
Beneficial Ownership Report
Paradigm BioCapital Advisors LP, its general partner, and its managing member, along with Paradigm BioCapital International Fund Ltd., have filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.5% in Disc Medicine, Inc.'s common stock as of March 31, 2025.
Summary
- Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. (managing member of the GP) collectively reported beneficial ownership of 1,210,971 shares of Disc Medicine, Inc. common stock.
- This aggregate ownership represents 3.5% of Disc Medicine, Inc.'s outstanding common stock.
- Paradigm BioCapital International Fund Ltd., a private investment vehicle managed by Paradigm BioCapital Advisors LP, directly beneficially owns 1,069,143 shares, representing 3.1% of the class.
- The percentages are based on 34,569,042 shares of Common Stock outstanding as of February 21, 2025, as reported by Disc Medicine, Inc. in its Form 10-K filed on February 27, 2025.
- The filing is an Amendment No. 3 to a Schedule 13G, indicating a change from a previous filing.
- The reporting persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual report of beneficial ownership, indicating a neutral sentiment. It does not contain information that would suggest positive or negative operational or financial performance.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive beneficial ownership by an investment firm in a publicly traded biotechnology company. It does not provide insights into broader industry trends or competitive landscape, but rather reflects an investment position by a specialized biotech investor.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant passive ownership stakes by institutional investors, which can be a signal of investor confidence or interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2025-02-21 | Date as of which 34,569,042 shares of Common Stock were reported outstanding by the Issuer in its Form 10-K. |
| 2025-02-27 | Date Disc Medicine, Inc. filed its Form 10-K with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G. |
| 2025-05-15 | Date the Schedule 13G Amendment No. 3 was signed and filed. |
Keywords
Disc Medicine Inc., Paradigm BioCapital Advisors LP, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.